Business Context and Reporting Period
This Form 8-K Current Report was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on October 21, 2022. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report details a specific financing event occurring on the date of the report.
Key Financial Metrics and Obligations
- Debt Financing: AgeX borrowed an additional $500,000 under a Secured Convertible Promissory Note with Juvenescence Limited.
- Total Drawn: The cumulative amount borrowed under the line of credit is now $11,660,000.
- Remaining Capacity: $1,500,000 remains available for future draws, subject to lender discretion and a $1 million cap per single draw.
- Maturity Date: The outstanding principal balance is due on February 14, 2024.
- Cost of Capital: In lieu of accrued interest, the company pays an Origination Fee of 4% on each draw and an additional 4% on the total funds drawn after the 12-month draw period.
- Equity Issuance: In connection with the $500,000 draw, AgeX issued warrants to purchase 362,318 shares of common stock at an exercise price of $0.69 per share.
Material Changes
The primary material change reported is the increase in indebtedness by $500,000 and the corresponding issuance of unregistered equity securities (warrants). This action increases the total principal obligation under the existing Secured Note to $11.66 million. The filing does not provide comparative revenue, profit, or cash flow data for the period.
Outlook, Risks, and Contingencies
Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
Events of Default: The Secured Note contains extensive default provisions that could trigger immediate repayment of the entire outstanding balance. Key triggers include:
- Failure to pay principal or other amounts within specified grace periods.
- Failure to perform covenants or satisfy conditions.
- Other indebtedness exceeding $100,000 becoming due early or indebtedness over $25,000 not being paid on time.
- Insolvency, bankruptcy proceedings, or inability to pay debts as they fall due.
- Disposition of material assets (fair value of at least $250,000) without approval.
- Material adverse changes in financial condition or loss of collateral.
Liquidity Contingency: Future draws are subject to Juvenescence's discretion, meaning the company cannot guarantee access to the remaining $1.5 million credit line.
Investor Verification Checklist
- Verify the total outstanding debt of $11.66 million and the remaining $1.5 million credit availability.
- Confirm the repayment schedule and the specific calculation of the 8% total Origination Fee structure.
- Review the terms of the warrants issued (362,318 shares at $0.69 exercise price) and their listing status on NYSE American.
- Assess the company's current cash position against the February 14, 2024, maturity date to evaluate refinancing or repayment risks.
- Monitor for any "Events of Default" that could accelerate the debt obligation.